Please assess the completion status of the following clinical trial:

Trial Title: ADVM-022 Intravitreal Gene Therapy for Wet AMD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 50~* Diagnosis of neovascular (wet) AMD~* BCVA ETDRS Snellen equivalent between ≤20/32 and ≥20/320 for each cohort~* Subjects must be under active anti-VEGF treatment for wAMD and received a minimum of 2 injections within 4 months prior to screening~* Demonstrated a meaningful response to anti-VEGF therapy~* Willing and able to provide consent~Exclusion Criteria:~* History of retinal disease in the study eye other than wet AMD~* Fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study eye, or any condition preventing visual acuity improvement~* History of retinal detachment (with or without repair) in the study eye~* History of vitrectomy, trabeculectomy, or other filtration surgery in the study eye~* Uncontrolled glaucoma in the study eye~* Any prior treatment with photodynamic therapy or retinal laser for the treatment of wet AMD and any previous therapeutic radiation in the region of the study eye~* Any previous intraocular or periocular surgery on the study eye within 6 months~* Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, TIA in the last 6 months~* Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose 1 (Type: EXPERIMENTAL): 6E11 vg of ADVM-022
- Dose 2 (Type: EXPERIMENTAL): 2E11 vg of ADVM-022

Based on this trial design, predict the completion outcome and termination type (if applicable).